Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: $BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bausch + Lomb Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bausch + Lomb Corporation's position in the market.
Bausch + Lomb (NYSE/TSX: BLCO) reported first-quarter 2024 results, with revenue reaching $1.099 billion, a GAAP net loss of $167 million, and an adjusted EBITDA of $180 million. The revenue grew by 18% as reported and 20% on a constant currency basis compared to the first quarter of 2023. The company experienced broad-based growth across all business segments and key franchises, with strong performance in Vision Care, Surgical, and Pharmaceuticals segments. The positive financial results were driven by growth in Daily SiHy lenses, LUMIFY, and eye vitamins, along with successful launches of MIEBO and XIIDRA. Bausch + Lomb also raised its full-year 2024 constant currency revenue growth guidance.
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
Summary: Bausch + Lomb (NYSE/TSX: BLCO) has revealed the presentation of 21 scientific posters at the Association for Research in Vision and Ophthalmology Annual Meeting. The posters showcase evaluations of consumer, pharmaceutical, surgical, and vision care products, as well as pipeline programs. Notably, a new dry eye nutritional supplement, Blink™ NutriTears®, stands out among the offerings. The company's commitment to advancing eye care through research and innovation is evident in this comprehensive display of data.
